Evidence map›Paper›PMID 36039183›Full record

ArticleAmerican journal of preventive cardiology2022

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

Peter P Toth, Gregory G Schwartz, Stephen J Nicholls, Aziz Khan, Michael Szarek, Henry N Ginsberg, Jan O Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Ken Lebioda and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Epigenetic mechanisms mediate cytochrome P450 1A1 expression and lung endothelial injury caused by MRSA in vitro and in vivo.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Peter P TothCGH Medical Center Sterling, Sterling, IL, USA.
Gregory G SchwartzDivision of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
Stephen J NichollsMonash Cardiovascular Research Centre, Monash University, Melbourne, Australia.
Aziz KhanResverlogix Corp., Calgary, Alberta, Canada.
Michael SzarekCPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Henry N GinsbergDepartment of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.
Jan O JohanssonResverlogix Corp., Calgary, Alberta, Canada.
Kamyar Kalantar-ZadehDivision of Nephrology and Hypertension, University of California Irvine, Irvine, CA, USA.
Ewelina KulikowskiResverlogix Corp., Calgary, Alberta, Canada.
Ken LebiodaResverlogix Corp., Calgary, Alberta, Canada.
Norman C W WongResverlogix Corp., Calgary, Alberta, Canada.
Michael SweeneyResverlogix Corp., Calgary, Alberta, Canada.
Kausik K RayImperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK.
BETonMACE Investigators
Resverlogix (Canada) · CAColumbia University · USImperial College London · GBJohns Hopkins University · USMonash University · AUState University of New York · USUniversity of California, Irvine · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk for coronary atherosclerosis and acute cardiovascular (CV) events. We employed the validated, non-invasive Angulo NAFLD fibrosis score (FS) in an intervention study in patients with T2DM and recent acute coronary syndrome (ACS) to determine the association of FS with CV risk and treatment response to apabetalone. Apabetalone is a novel selective inhibitor of the second bromodomain of bromodomain and extra-terminal (BET) proteins, epigenetic regulators of gene expression. Methods: The Phase 3 BETonMACE trial compared apabetalone with placebo in 2,425 patients with T2DM and recent ACS. In this Results: In 73.7% of patients, FS was elevated and consistent with a moderate-to-high likelihood of advanced liver fibrosis (FS+); 26.3% of patients had a lower FS (FS Conclusions: Amongst patients with T2DM, recent ACS, and a moderate-to-high likelihood of advanced liver fibrosis, apabetalone was associated with a significantly lower rate of ischemic MACE and HHF and attenuated the increase in hepatic FS over time.

Indexed as

ACS, Acute coronary syndromeALP, Alkaline PhosphataseALT, Alanine aminotransferaseApabetaloneApoAI, Aproprotein-AIAPR, Acute phase reactantAST, Aspartate aminotransferaseBD, BromodoaminBET, Bromodomain and extraterminal proteinfamilyBMI, Body mass indexCardiovascular eventsCV, CardiovascularCVD, Cardiovascular DiseaseFibrosisFS, Fibrosis scoreHDL-C, High density lipoprotein cholesterolHHF, Hospitalization for heart FailureHR, Hazard ratioMACE, Major acute coronary eventNAFLD, Nonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseT2DM, Type 2 diabetes mellitus

Identifiers

PMID36039183
PMCPMC9419281
OpenAlexW4292330677

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.